Regen Biopharma, Inc.
Records under this name other than the patents Regen Biopharma, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.
Showing 1 to 7 of 7 · Back to Regen Biopharma, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,091,696 | Modulation of NR2F6 and methods and uses thereof Formerly held In force · High confidence | In force | High confidence | |
| US 10,088,485 | Methods of Screening Compounds That Can Modulate NR2F6 by Displacement of a Reference Ligand Formerly held Lapsed on the fee record Ended Oct 2, 2026 · High confidence | Lapsed on the fee record | Ended Oct 2, 2026 | High confidence |
| US 11,377,442 | Small Molecule Agonists and Antagonists of NR2F6 Activity Formerly held Lapsed on the fee record Ended Jul 5, 2026 · High confidence | Lapsed on the fee record | Ended Jul 5, 2026 | High confidence |
| US 11,324,719 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans Formerly held Lapsed on the fee record Ended May 10, 2026 · High confidence | Lapsed on the fee record | Ended May 10, 2026 | High confidence |
| US 11,141,471 | Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells Lapsed on the fee record Ended Oct 12, 2025 · USPTO record | Lapsed on the fee record | Ended Oct 12, 2025 | USPTO record |
| US 11,090,332 | Antigen specific mRNA cellular cancer vaccines Lapsed on the fee record Ended Aug 17, 2025 · USPTO record | Lapsed on the fee record | Ended Aug 17, 2025 | USPTO record |
| US 8,389,708 | Method of cancer treatment using siRNA silencing Lapsed on the fee record Ended Mar 5, 2025 · USPTO record | Lapsed on the fee record | Ended Mar 5, 2025 | USPTO record |